- Recommendation ID
- TA283/1
- Question
- NICE concluded that further research directly comparing the clinical and cost effectiveness of ranibizumab and bevacizumab in people with macular oedema secondary to retinal vein occlusion should be conducted.
- Any explanatory notes
(if applicable) - None.
Source guidance details
- Comes from guidance
- Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
- Number
- TA283
- Date issued
- May 2013
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 13/06/2013 |